CNPR Clinical Trials 4 — Questions and Answers
Question 1: What is the purpose of a wash-out period in a clinical trial?
- To cleanse manufacturing equipment between production batches
- To allow effects of a prior treatment to dissipate before starting the next treatment period (Correct answer)
- To remove participants who experienced adverse events
- To purge incomplete data from the trial database
Correct answer: To allow effects of a prior treatment to dissipate before starting the next treatment period
A wash-out period allows a previously administered drug to clear from the body so its effects do not carry over and confound results in the next treatment period.
Question 2: Under Good Clinical Practice (GCP) guidelines, how long must trial records typically be retained after trial completion?
- 1 year
- 2 years
- At least 2 years after the last marketing approval (Correct answer)
- 5 years after the trial ends
Correct answer: At least 2 years after the last marketing approval
ICH E6 GCP guidelines require essential documents to be retained for at least 2 years after the last marketing approval or after the investigational drug is discontinued.
Question 3: What is the primary function of an Institutional Review Board (IRB)?
- To fund clinical research studies
- To protect the rights, safety, and welfare of human research participants (Correct answer)
- To manufacture investigational drugs for trials
- To submit New Drug Applications to the FDA
Correct answer: To protect the rights, safety, and welfare of human research participants
An IRB independently reviews research protocols and informed consent documents to protect the rights, safety, and welfare of human research subjects.
Question 4: What is a 'serious adverse event' (SAE) in clinical trial reporting?
- Any side effect that causes mild discomfort
- An adverse event that results in death, hospitalization, disability, or is life-threatening (Correct answer)
- An event that causes a participant to miss one study visit
- Any adverse event not listed in the investigator brochure
Correct answer: An adverse event that results in death, hospitalization, disability, or is life-threatening
An SAE is defined as any adverse event resulting in death, life-threatening condition, inpatient hospitalization, persistent disability, or congenital anomaly.
Question 5: What does 'blinding' in a clinical trial primarily prevent?
- Participant dropout
- Bias in treatment assessment and reporting (Correct answer)
- Protocol deviations by investigators
- Recruitment of ineligible participants
Correct answer: Bias in treatment assessment and reporting
Blinding prevents knowledge of treatment assignment from influencing participant behavior or investigator assessment, thereby reducing measurement and reporting bias.
Question 6: Which type of clinical trial design is most appropriate for rare diseases with very small patient populations?
- Large parallel-group randomized trial
- N-of-1 or adaptive trial design (Correct answer)
- Phase III multi-center superiority trial
- Open-label extension study
Correct answer: N-of-1 or adaptive trial design
N-of-1 designs or adaptive trial designs are particularly valuable for rare diseases because they maximize information from small populations through flexible statistical approaches.
Question 7: What is the significance of a p-value less than 0.05 in clinical trial results?
- The drug has demonstrated clinical meaningfulness
- There is a statistically significant difference unlikely due to chance alone (Correct answer)
- The drug is approved for marketing
- The trial achieved its enrollment target
Correct answer: There is a statistically significant difference unlikely due to chance alone
A p-value < 0.05 indicates there is less than a 5% probability the observed result occurred by chance, meeting the conventional threshold for statistical significance.
CNPR Clinical Trials 4
What is the purpose of a wash-out period in a clinical trial?